Although expression of isolated surface markers (e.g., CD34, CD117, CD90, CD25, CD7, CD56, and more) has been linked to poor prognosis in AML, the “poor prognostic immunophenotype” in AML remains elusive. This evidence concerns the gene NCAM1 and acute myeloid leukemia.